|
1
|
Ghazanfari N, van Waarde A, Doorduin J, Sijbesma JWA, Kominia M, Koelewijn M, Attia K, Vállez-García D, Willemsen ATM, Heeres A, Dierckx RAJO, Visser TJ, de Vries EFJ, Elsinga PH. Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D 2 and Histamine H 3 Receptors: A PET Study in Healthy Rats. Mol Pharm 2022; 19:2287-2298. [PMID: 35732005 PMCID: PMC9257755 DOI: 10.1021/acs.molpharmaceut.2c00121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
![]()
Introduction: Parkinson’s disease (PD) is a
neurodegenerative disorder characterized by motor dysfunction and
a diverse range of nonmotor symptoms. Functional relationships between
the dopaminergic and histaminergic systems suggest that dual-action
pharmaceuticals like AG-0029 (D2/D3 agonist/H3 antagonist) could ameliorate both the motor and cognitive
symptoms of PD. The current study aimed to demonstrate the interaction
of AG-0029 with its intended targets in the mammalian brain using
positron emission tomography (PET). Methods: Healthy
male Wistar rats were scanned with a small-animal PET camera, using
either the dopamine D2/D3 receptor ligand [11C]raclopride or the histamine H3 receptor ligand
[11C]GSK-189254, before and after treatment with an intravenous,
acute, single dose of AG-0029. Dynamic [11C]raclopride
PET data (60 min duration) were analyzed using the simplified reference
tissue model 2 (SRTM2) with cerebellum as reference tissue and the
nondisplaceable binding potential as the outcome parameter. Data from
dynamic [11C]GSK-189254 scans (60 min duration) with arterial
blood sampling were analyzed using Logan graphical analysis with the
volume of distribution (VT) as the outcome
parameter. Receptor occupancy was estimated using a Lassen plot. Results: Dopamine D2/3 receptor occupancies in
the striatum were 22.6 ± 18.0 and 84.0 ± 3.5% (mean ±
SD) after administration of 0.1 and 1 mg/kg AG-0029, respectively.
In several brain regions, the VT values
of [11C]GSK-189254 were significantly reduced after pretreatment
of rats with 1 or 10 mg/kg AG-0029. The H3 receptor occupancies
were 11.9 ± 8.5 and 40.3 ± 11.3% for the 1 and 10 mg/kg
doses of AG-0029, respectively. Conclusions: Target engagement
of AG-0029 as an agonist at dopamine D2/D3 receptors
and an antagonist at histamine H3 receptors could be demonstrated
in the rat brain with [11C]raclopride and [11C]GSK-189254 PET, respectively. The measured occupancy values reflect
the previously reported high (subnanomolar) affinity of AG-0029 to
D2/D3 and moderate (submicromolar) affinity
to H3 receptors.
Collapse
Affiliation(s)
- Nafiseh Ghazanfari
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Aren van Waarde
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Janine Doorduin
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Jürgen W A Sijbesma
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Maria Kominia
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | | | - Khaled Attia
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - David Vállez-García
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Antoon T M Willemsen
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - André Heeres
- Symeres B.V., Kadijk 3, 9747 AT Groningen, The Netherlands
| | - Rudi A J O Dierckx
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Ton J Visser
- Symeres B.V., Kadijk 3, 9747 AT Groningen, The Netherlands
| | - Erik F J de Vries
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| | - Philip H Elsinga
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
| |
Collapse
|